Strongyloidiasis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
Line 16: Line 16:
*Use of oral or intravenous [[steroids]] for example, in patients with [[asthma]], [[chronic obstructive pulmonary disease]] ([[COPD]]) exacerbations, [[lupus]], [[gout]], or in persons using [[steroids]] for [[immunosuppression]] or symptomatic relief.
*Use of oral or intravenous [[steroids]] for example, in patients with [[asthma]], [[chronic obstructive pulmonary disease]] ([[COPD]]) exacerbations, [[lupus]], [[gout]], or in persons using [[steroids]] for [[immunosuppression]] or symptomatic relief.
*[[HTLV-1]] infection
*[[HTLV-1]] infection
*[[hematologic]] [[malignancies]] such as [[leukemia]] or [[lymphoma]]
*[[Hematologic]] [[malignancies]] such as [[leukemia]] or [[lymphoma]]
*[[Transplant|Transplant recipients]]
*[[Transplant|Transplant recipients]]



Revision as of 17:42, 28 July 2017

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis natural history, complications and prognosis

CDC on Strongyloidiasis natural history, complications and prognosis

Strongyloidiasis natural history, complications and prognosis in the news

Blogs on Strongyloidiasis natural history, complications and prognosis

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis natural history, complications and prognosis

Overview

If left untreated, the subclinical strongyloidiasis can disseminate and transform into hyper infection syndrome with a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis, especially in patients with HIV or an otherwise weakened immune system, eosinophilic pneumonia and malnutrition due to problems absorbing nutrients from the gastrointestinal tract (malabsorption). With good treatment, people should make a full recovery. Often Sometimes treatment needs to be repeated. Infections that are severe or widespread often have a poor outcome, especially in people with a weakened immune system.[1]

Natural history

If left untreated, the subclinical strongyloidiasis can disseminate and transform into hyper-infection syndrome with a mortality rate of 90%.

Complications

Complications that can develop as a result of strongyloidiasis are

Prognosis

With good treatment, people should make a full recovery. Often Sometimes treatment needs to be repeated. Infections that are severe or widespread often have a poor outcome, especially in people with a immunosuppression. Strongyloidiasis could be severe and life-threatening in persons specific groups which includes:

References

  1. Beknazarova M, Whiley H, Ross K (2016). "Strongyloidiasis: A Disease of Socioeconomic Disadvantage". Int J Environ Res Public Health. 13 (5). doi:10.3390/ijerph13050517. PMC 4881142. PMID 27213420.

Template:WH Template:WS